Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report), with a price target of $75.00.
Patrick Trucchio’s Buy rating for Silence Therapeutics is based on the potential of the company’s RNAi platform and upcoming key data readouts for its leading drug candidates. These candidates include zerlasiran for cardiovascular disease treatment, and SLN124 for a rare blood cancer, polycythemia vera. Trucchio highlights the underappreciation by investors of these programs and anticipates that forthcoming clinical results will demonstrate competitive advantages in the market, particularly for zerlasiran, which may lead to valuable partnerships.
Trucchio’s confidence in the Buy rating is reinforced by the expected positive outcomes from the ALPACAR-360 trial for zerlasiran. Previous top-line results have shown significant reductions in Lp(a) levels with a favorable safety profile, which suggests strong potential for Phase 3 advancement and collaboration opportunities. Additionally, the SANRECO trial readouts for SLN124 are anticipated to provide initial proof of efficacy in treating polycythemia vera, further underpinning the optimistic outlook for Silence Therapeutics’ stock.
Trucchio covers the Healthcare sector, focusing on stocks such as Oncolytics Biotech, Alnylam Pharma, and Altimmune. According to TipRanks, Trucchio has an average return of -9.9% and a 30.15% success rate on recommended stocks.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Silence Therapeutics (SLN) Company Description:
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.
Read More on SLN:
